Intrathecal Pemetrexed for Leptomeningeal Metastases in Lung Cancer
Author Information
Author(s): Emelie Gezelius, Maria Planck, Bassam Hazem, Seema Nagpal, Heather Wakelee
Primary Institution: Lund University
Hypothesis
Can intrathecal pemetrexed provide clinical benefit for patients with leptomeningeal metastases from lung adenocarcinoma?
Conclusion
Intrathecal pemetrexed may offer symptomatic relief and clinical improvement in patients with progressive leptomeningeal metastases due to lung adenocarcinoma.
Supporting Evidence
- Intrathecal pemetrexed rapidly improved the patient's neurological symptoms.
- The patient regained visual acuity and was able to walk short distances after treatment.
- Treatment was well tolerated with minimal side effects.
Takeaway
This study shows that a special medicine called intrathecal pemetrexed can help people with a type of brain cancer caused by lung cancer feel better.
Methodology
The patient received intrathecal pemetrexed and was monitored for clinical improvement and side effects.
Limitations
The study is based on a single case report, limiting generalizability.
Participant Demographics
A 47-year-old woman with a 10-year history of metastatic ALK-positive NSCLC.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website